PhenoMed Sdn Bhd Initiating Clinical Trials Program for SARS and Other Infectious Diseases
KUALA LUMPUR, Malaysia, Jan 26, 2004 /PRNewswire via COMTEX/ -- PhenoMed Sdn
Bhd, a development-stage disease management and medical-pharmaceutical
therapeutic company, announces the initiation of its clinical trials program for
infectious diseases.
"PhenoMed is announcing that it will begin collecting information from
government agencies, physicians and individual patients interested in
participating in the company's clinical trials program. We are working closely
with our US partner, GenoMed, Inc., and that company's CEO and Chief Medical
Officer, Dr. David Moskowitz, in helping to sign up interested parties," said
Ezehan Reza Kamaluddin, PhenoMed's interim Chief Operating Officer. "There is a
worldwide need for disease management and targeted pharmaceutical therapeutics
directed at infectious disease. Malaysia's disease management needs are
ever-present and PhenoMed wants to do all it can to help in meeting the
country's healthcare needs. The immediate concerns over avian flu in the region
highlights this need."
PhenoMed's US partner, GenoMed, believes it has discovered a way to accomplish
the equivalent of vaccination against all viruses, a kind of "universal vaccine"
against most viral diseases. The method involves blocking angiotensin II, an
approach already known to be extremely safe from its use, for other purposes, in
hundreds of millions of patients since 1978. This patent-pending method is
presently under study by the National Institute of Allergy and Infectious
Diseases (NIAID), part of NIH, to test the Company's compounds in tissue culture
assays to evaluate potential activity against influenza (the flu) and SARS.
About PhenoMed, Sdn Bhd
PhenoMed is a development-stage disease management and medical- pharmaceutical
therapeutic company, with its primary goal being the improvement of patient
outcomes through the discovery and application of "genome-aware
therapeutics(TM)". PhenoMed is building a network of physician and health
services organizations to quickly expand its medical and therapeutic service
offerings throughout the Asia-Pacific region. Founded in 2003, PhenoMed is a
privately held company located in Kuala Lumpur, Malaysia. For more information
about the company, please visit phenomed.net.
PhenoMed Contact:
Corporate Headquarters
Ezehan Reza Kamaluddin
Chief Operating Officer (Interim)
28-1, Level 1, Jalan 28/70A
Desa Sri Hartamas
50480 Kuala Lumpur, Malaysia
ezehan@dnaphenomics.com
www.phenomed.net
About GenoMed, Inc.
GenoMed, Inc. is a next generation disease management company whose mission is
the improvement of patient outcomes through the identification of molecular
pathways that cause disease. As first reported in a St. Louis Business Journal
article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html), the
company has applied for patents based on its finding that the ACE gene is
associated with a large number of common diseases including virtually all
autoimmune diseases. GenoMed is currently conducting worldwide clinical trials
for SARS and influenza A (the flu). In September of 2003, GenoMed obtained an
88% cure rate for this treatment approach against another lethal viral disease,
West Nile virus encephalitis. These results will be published soon.
GenoMed Contact:
David W. Moskowitz MD, MA (Oxon.), FACP
314-977-0110
fax: 314-977-0042
dwmoskowitz@genomedics.com
www.genomedics.com
This release was issued through eReleases(TM). For more information, visit ereleases.com.
SOURCE PhenoMed Sdn Bhd
CONTACT: Ezehan Reza Kamaluddin, Chief Operating Officer (Interim),
PhenoMed, ezehan@dnaphenomics.com; or David W. Moskowitz MD, MA (Oxon.), FACP,
GenoMed, +1-314-977-0110, fax: +1-314-977-0042, dwmoskowitz@genomedics.com
URL:
genomedics.com
phenomed.net |
